DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

Recruiting

Conditions: Sickle Cell Disease

Interventions: Other: OTQ923

First Posted Date: 2023-12-04

Last Posted Date: 2024-05-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5

Registration Number: NCT06155500

Locations: 🇺🇸
St Jude Childrens Rsrch Hospital, Memphis, Tennessee, United States

A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: sacubitril/valsartan

First Posted Date: 2023-11-28

Last Posted Date: 2025-02-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT06149104

Locations: 🇯🇵
Novartis Investigative Site, Toyama, Japan

A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia

Recruiting

Conditions: HR+HER2- Advanced Breast Cancer

Interventions: Other: Ribociclib
Other: Combination chemotherapy

First Posted Date: 2023-11-28

Last Posted Date: 2025-01-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 376

Registration Number: NCT06148506

Locations: 🇷🇺
Novartis Investigative Site, Yaroslavl, Russian Federation

Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database

Completed

Conditions: Chronic Myeloid Leukemia

First Posted Date: 2023-11-28

Last Posted Date: 2023-11-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 425

Registration Number: NCT06148493

Locations: 🇺🇸
Novartis, East Hanover, New Jersey, United States

Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis

Recruiting

Conditions: Moderate-to-severe Plaque Psoriasis

Interventions: Other: Secukinumab

First Posted Date: 2023-11-21

Last Posted Date: 2025-03-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT06142357

Locations: 🇷🇺
Novartis Investigative Site, Yakutsk, Russian Federation

A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure

Phase 2

Terminated

Conditions: Heart Failure

Interventions: Biological: Placebo
Biological: XXB750 Low dose
Biological: XXB750 High Dose
Biological: XXB750 Medium Dose
Drug: Sacubitril/valsartan

First Posted Date: 2023-11-21

Last Posted Date: 2024-11-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 720

Registration Number: NCT06142383

Locations: 🇺🇸
SEC Clinical Research Research, Dothan, Alabama, United States
🇺🇸
Heart Center Research Llc ., Huntsville, Alabama, United States
🇺🇸
Pima Heart And Vascular Clin Rch Research, Tucson, Arizona, United States

and more 41 locations

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

Phase 3

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Ianalumab
Drug: Placebo

First Posted Date: 2023-11-18

Last Posted Date: 2025-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 550

Registration Number: NCT06133972

Locations: 🇺🇸
Pinnacle Research Group Llc, Anniston, Alabama, United States
🇺🇸
Advanced Medical Research, La Palma, California, United States
🇺🇸
Millennium Clinical Trials, Westlake Village, California, United States

and more 7 locations

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

Phase 1

Active, not recruiting

Conditions: Giant Cell Arteritis
Polymyalgia Rheumatica

Interventions: Drug: Secukinumab

First Posted Date: 2023-11-14

Last Posted Date: 2025-03-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 65

Registration Number: NCT06130540

Locations: 🇺🇸
Rheumatology Associates of South Florida, Boca Raton, Florida, United States
🇺🇸
FL Medical Clinic Orlando Health, Zephyrhills, Florida, United States
🇺🇸
Willow Rheumatology Wellness, Willowbrook, Illinois, United States

and more 11 locations

WOE of Anti-CD20 Therapies

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: ocrelizumab
Drug: ofatumumab

First Posted Date: 2023-11-07

Last Posted Date: 2025-03-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 150

Registration Number: NCT06121349

Locations: 🇺🇸
Novartis Investigational site, East Hanover, New Jersey, United States

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Phase 2

Completed

Conditions: Coronary Heart Disease
Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Interventions: Drug: MAS825 Placebo
Drug: MAS825
Drug: DFV890
Drug: DFV890 placebo

First Posted Date: 2023-10-24

Last Posted Date: 2024-12-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT06097663

Locations: 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸
Vanderbilt University Medical Cent, Nashville, Tennessee, United States
🇩🇪
Novartis Investigative Site, Muenchen, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy